Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/101177
Título: | Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations | Autor: | Carda, José Pedro Santos, Lurdes Mariz, José Mário Monteiro, Pedro Gonçalves, Humberto Miguel Raposo, João Silva, Maria Gomes da |
Palavras-chave: | B-cell malignancies; Bruton tyrosine kinase inhibitor; ibrutinib; recommendations | Data: | Dez-2021 | Projeto: | The project received financial support from Janssen for logistics of expert meetings and editorial support. | Título da revista, periódico, livro ou evento: | Hematology (United Kingdom) | Volume: | 26 | Número: | 1 | Resumo: | Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice. | URI: | https://hdl.handle.net/10316/101177 | ISSN: | 1607-8454 | DOI: | 1607-8454 34605364 10.1080/16078454.2021.1980690 34605364 1607-8454 |
Direitos: | openAccess |
Aparece nas coleções: | I&D ICBR - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Management-of-ibrutinib-treatment-in-patients-with-Bcell-malignancies-clinical-practice-in-Portugal-and-multidisciplinary-recommendationsHematology-United-Kingdom.pdf | 2.3 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
2
Visto em 23/set/2024
Citações WEB OF SCIENCETM
2
Visto em 2/set/2024
Visualizações de página
85
Visto em 25/set/2024
Downloads
130
Visto em 25/set/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons